menu
    • menu
    [{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Visus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Inhalation","sponsorNew":"Zhaoke Ophthalmology \/ Zhaoke Ophthalmology","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Ophthalmology \/ Zhaoke Ophthalmology"}]

    Find Clinical Drug Pipeline Developments & Deals by Zhaoke Ophthalmology

    Menu

    Zhaoke Ophthalmology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zhaoke Ophthalmology

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Zhaoke Ophthalmology

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbachol,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Visus Therapeutics

                            Deal Size : $130.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercia...

                            Details : Under the terms of the agreement, ZKO will be responsible for clinical development and regulatory approval for BRIMOCHOL PF and Carbachol PF in the specified territories, and subsequently the commercialization activities for the products.

                            Brand Name : Brimochol

                            Molecule Type : Small molecule

                            Upfront Cash : $15.0 million

                            May 11, 2022

                            Lead Product(s) : Carbachol,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Visus Therapeutics

                            Deal Size : $130.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth